Head-to-head evidence
ABP-745 vs AZD4144
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: NLRP3 inflammasome · full Atherosclerotic Cardiovascular Disease pipeline
ABP-745
Developed by Atom Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2028 · NCT07303777 (registry estimate)
AZD4144
Developed by AstraZeneca
NCT06675175 · Phase 1 · completed
The trial is randomized, blinded, and placebo-controlled, but its two co-primary measures are safety and a blood inflammation marker rather than a clinical disease outcome, and no results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABP-745's landscape · AZD4144's landscape